Ruminant Vaccines Market Size, Share & Trends Analysis Report By Animal Type (Cattle, Sheep & Goats), By Vaccine Type (Modified/Attenuated Live), By Indication, By Route Of Administration, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global ruminant vaccines market size was valued at USD 3.28 billion in 2022 and is estimated to grow at a compound annual growth rate (CAGR) of 6.95% from 2023 to 2030. Key drivers contributing to this growth include increasing demand for animal protein, initiatives by key companies, R&D activities, increasing prevalence of diseases, and focus on biosecurity. In December 2022, Ceva Santé Animale acquired Zoovet, which specializes in the manufacturing and marketing of veterinary products, and Biotecnofe, which specializes in the development of innovative biotech products, both in Argentina. This strengthened the company’s presence in Latin America as well as its capabilities for innovation, particularly for ruminants.

The COVID-19 pandemic, as well as the macroeconomic headwinds of 2022, notably impacted the market. This included supply chain challenges, operational hurdles, the rise of input costs, as well as increased awareness for disease prevention. In 2022, Zoetis, for instance, reported a decline in the U.S. sales of its cattle products owing to supply constraints, generic competition, dry weather conditions, and increased input costs. However, the company witnessed improved sales in this area in markets such as Australia, Argentina, Turkey, and China due to favorable market conditions and prices.

Boehringer Ingelheim International GmbH, another key market player, reported a notable impact of the economic slowdown on its animal health business in Europe and North America in 2022. The company reported dampened growth in 2022 owing to consumer behavior adjustments because of high inflation as well as supply chain hurdles. In 2023, the company has projected moderate growth in the animal health market. Elanco, too, reported an adverse impact on its business and profitability due to the pandemic, supply chain issues, and shortage of raw materials. The company expects a continued impact of the macroeconomic factors on its business in 2023.

The growing consumer demand for animal welfare and food safety drives the use of ruminant vaccines. Consumers are becoming more conscious regarding animal welfare and the safety of animal-derived products they consume. They prefer products from animals that are healthy, well-cared for, and not treated with excessive antibiotics. Vaccination plays a crucial role in preventing diseases and reducing the need for antibiotics in livestock. In 2022, Virbac reported an increase in investments in its centers for R&D and production of livestock vaccines in Australia, Chile, France, Taiwan, and Uruguay, as a means to reduce the use of antibiotics in animal production.

Animal Type Insights

The cattle segment dominated the market with 85% of the revenue share in 2022. However, the sheep & goats segment is projected to expand at the fastest CAGR of over 9% during the projection period. The global population is rising continuously, leading to rising demand for animal protein, including meat and dairy products. Ruminant livestock, such as cattle, sheep, and goats, play a significant role in meeting this demand. To ensure the health and productivity of these animals, vaccines are essential in preventing and controlling infectious diseases, thus driving the demand for ruminant vaccines.

As per the FAO and internal GVR estimates, the global cattle population has increased from about 1.4 billion in 2018 to 1.5 billion in 2022. Similarly, the sheep and goat populations increased from 1.2 and 1.0 billion in 2018 to 1.3 and 1.1 billion in 2022, respectively. Several key companies, such as Zoetis, Merck, Ourofino Animal Health, and Ceva Santé Animale, offer vaccines for ruminants. The growing ruminant population combined with the increasing availability of vaccines is thus expected to propel market growth in the coming years.

Vaccine Type Insights

By vaccine type, the Modified/ Attenuated Live Vaccines segment contributed to the highest market share of over 52% in 2022. This is due to a notable number of ruminant vaccines being available in modified or live attenuated form, as well as the benefits associated with these vaccines. In June 2023, Bimeda Biologicals enhanced its portfolio of modified live virus (MLV) vaccines with the launch of Stimulator 5 + PMH combination vaccine to protect cattle against major Bovine Respiratory Diseases (BRD). The vaccine is effective against Bovine Viral Diarrhea, Infectious Bovine Rhinotracheitis (IBR), Bovine Respiratory Syncytial Virus (BRSV), and Parainfluenza3 (PI3).

On the other hand, the other vaccines segment is estimated to expand at the highest rate of 9.4% during the forecast period. This growth is driven by significant advancements in recent years in the field of veterinary medicine, especially the development of innovative vaccine technologies. These technologies enhance the efficacy, safety, and ease of administration of vaccines. For example, the development of recombinant, DNA, and toxoid vaccines has expanded the options for disease prevention in ruminants. ‘Bovi-shield gold one shot’ from Zoetis, for instance, is a toxoid vaccine indicated for action against Mannheimia haemolytica in cattle.

Route of Administration Insights

Based on the route of administration, the injectable segment held the dominant market share of around 95.0% in 2022 while the intranasal segment is anticipated to expand at the fastest CAGR of about 10%. The injectable route has numerous advantages, such as direct delivery to the bloodstream, dosage control, and better immune response, making it a widely adopted route of administration in the ruminant vaccines sector. The Pyramid/ Presponse family of vaccines from Boehringer Ingelheim, for example, is a lineup of injectable cattle vaccines effective against various bacteria and viruses.

The intranasal route, on the other hand, is a non-invasive route and offers ease of administration.INFORCE 3 from Zoetis, for instance, is an intranasal cattle vaccine for vaccination against respiratory disease caused by bovine respiratory syncytial virus (BRSV), parainfluenza 3 (PI3) virus, and infectious bovine rhinotracheitis (IBR) virus. It is intended for use in beef and dairy cattle.BOVILIS NASALGEN 3-PMH is another example of an intranasal vaccine provided by Merck, a leading player in the ruminant vaccines market.

Indication Insights

In terms of indication, the Bovine Respiratory Diseases (BRD) segment held the highest revenue share of about 35% of the market in 2022. The segment includes respiratory diseases of multifactorial etiology, such as bacterial infections caused by Mannheimia haemolytica and Mycoplasma bovis. It also includes diseases caused by viral pathogens such as parainfluenza-3 virus, bovine herpesvirus 1 (IBR), and bovine respiratory syncytial virus (BRSV). Increasing respiratory disease prevalence as well as initiatives to develop alternatives to antibiotics is expected to fuel segment growth.

The other indications segment is projected to grow at the highest rate of over 9% in the coming years. The segment includes diseases such as Bluetongue, Johne’s disease, Pinkeye/ IBK, Peste des Petits Ruminants, and scabby mouth disease. The segment growth is attributed to the increasing prevalence of diseases in ruminants as well as the growing availability of vaccines targeting these diseases. Ruminant diseases can cause significant economic losses due to reduced productivity, high mortality rates, and trade restrictions. Vaccination is a critical measure to prevent and control these diseases, driving the demand for ruminant vaccines.

Regional Insights

North America dominated the market with a revenue share of more than 38% in 2022. This is owing to factors such as the presence of leading market players, increasing consumption of animal protein, and technological advancements in the region. Key companies including Zoetis Services LLC, Merck & Co., Inc., and Elanco are headquartered in the U.S., thus contributing to the dominant regional share. In February 2022, Merck entered into a 4-year strategic collaboration with Iowa State Universityto expedite the delivery of animal health solutions and address complex needs in the market.

On the other hand, the Asia Pacific is expected to advance at the fastest CAGR of almost 9% in the near future due to the region’s high ruminant population, increasing number of local market players, and rising awareness regarding animal health and food security.Indian Immunologicals Ltd., for instance, is an Indian company that develops, manufactures, and distributes a range of vaccines for cattle, sheep, and goats. Its vaccines are indicated for prevention against Bluetongue, Foot-and-mouth disease (FMD), Hemorrhagic Septicemia, and Enterotoxaemia.

Key Companies & Market Share Insights

Several prominent companies, including Zoetis, MSD Animal Health, Elanco, and Ceva Santé Animale, compete for a share in the market for ruminant vaccines. These companies have established themselves as key players through their wide product portfolios, strong distribution networks, and R&D capabilities.Market players also engage in strategic partnerships, collaborations, and acquisitions to strengthen their market position and enhance their product offerings.

These partnerships allow companies to leverage each other's strengths, access new markets, and expand their product portfolios. For example, in September 2021, Vaxxinova purchased Newport Laboratories, which specializes in custom-made vaccines for pigs and cattle, from Boehringer Ingelheim. This supported Vaxxinova’s growth objectives and added to its product portfolio for livestock producers and veterinarians. Some of the prominent players in the global ruminant vaccines market include:

• Boehringer Ingelheim International GmbH

• Zoetis Services LLC

• Vaxxinova International BV

• Merck & Co., Inc.

• Bimeda Animal Health Ltd. 

• Indian Immunologicals Ltd.

• Elanco

• Virbac

• Ceva Santé Animale

• CZ Vaccines S.A.U. (Zendal Group)

Ruminant Vaccines Market Report Scope

Global Ruminant Vaccines Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global ruminant vaccines market report on the basis of animal type, vaccine type, indication, route of administration, and region:

• Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Cattle

  • Sheep & Goats

• Vaccine Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Modified/ Attenuated Live

  • Inactivated (Killed)

  • Other Vaccines

• Indication Outlook (Revenue, USD Million, 2018 - 2030)

  • BVD Infection

  • Bovine Respiratory Diseases (BRD)

  • Leptospirosis

  • Clostridial diseases

  • Diarrhea/ Scours

  • FMD

  • Other Indications

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Injectable

  • Intranasal

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Netherlands

    • Rest of Europe

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Rest of Asia Pacific

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Rest of Latin America

  • Middle East & Africa

    • South Africa

    • Rest of MEA